Publications

Show Filters

Searches all publications.

Search Term

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-19
    E.g., 2018-02-19

Articles

254480 items
12:00 AM, Nov 15, 1993  |  BC Week In Review | Clinical News  |  Regulatory

Anergen regulatory update

ANRG received U.S. Patent No. 5,260,422 covering major histocompatibility complex-based compounds used in the induction of anergy, or non-responsiveness, in T cells. The patent covers soluble MHC class II-peptide complexes in pharmaceutical compositions as well...
12:00 AM, Nov 15, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

Saliva sales and marketing update

SALV's SDS International Ltd. European subsidiary signed a three-year exclusive distribution agreement with Charter Medical Ltd. of Zimbabwe to market SALV's Omni-SAL Saliva-collection device in 12 southern African countries. A minimum of 600,000 devices must...
12:00 AM, Nov 15, 1993  |  BioCentury | Strategy

BIOX to expand Synvisc marketing

BIOX to expand Synvisc marketing Biomatrix Inc., after accepting some compromises to push its Synvisc osteoarthritis treatment into Canada in 1992, now has its sights on a series of major market milestones through the first part...
12:00 AM, Nov 15, 1993  |  BC Week In Review | Clinical News  |  Clinical Status

CPC-111: Filed IND

Cypros Pharmaceutical Corp. (CYPR)   Product: CPC-111 small molecule cytoprotective to minimize damage to heart muscle tissue   Indication: Treat myocardial infarction   Status: Filed IND   ...
12:00 AM, Nov 15, 1993  |  BioCentury | Strategy

Pursestrings and shoestrings

All chief financial officers worth their salt know that they need to invoke the standard methods of controlling costs, linking operating milestones with financial planning, and that the best way to keep spending down is...
12:00 AM, Nov 15, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

Ecogen sales and marketing update

Biopesticide sales increased to $2 million in the third quarter ended Sept. 30 from $1.5 million in the quarter last year, driven mainly by increased sales of nematode and pheromone products. The loss was $2.3...
12:00 AM, Nov 15, 1993  |  BC Week In Review | Clinical News  |  Regulatory

Enzo regulatory update

The Enzo Diagnostics Inc. subsidiary received notice of allowance for a U.S. patent covering the nonradioactive detection of nucleic acids and its use in diagnostic applications. The patent covers a wide range of chemical modifications...
12:00 AM, Nov 15, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

Advanced Polymer sales and marketing update

Product sales increased to $3.4 million in the third quarter ended Sept. 30 from $1.3 million in the quarter last year. APOS attributed the growth to increasing sales of Exact acne treatment, the third-quarter introduction...
12:00 AM, Nov 15, 1993  |  BC Week In Review | Company News  |  Sales & Marketing

Enzon Inc. sales and marketing update

Enzon Inc. (ENZN)   Product sales rose slightly to $1.8 million in ENZN's first quarter ended Sept. 30 from $1.7 million in the quarter last year. ENZN sells Adagen, a treatment for a form of...
12:00 AM, Nov 15, 1993  |  BC Week In Review | Company News  |  Other News

Escagenetics other research news

ESCAgenetics Corp. (ESN)   ESN received a $50,000 Phase I SBIR from the National Cancer Institute to create taxoids that potentially will have higher efficacy than taxol and fewer side effects. ESN's PHYTOpharmaceuticals subsidiary...

Pages